In cancers where mutations in the MAPK pathway confer resistance to BRAF inhibitors, such as melanoma, these exosome-encapsulated siRNAs can silence MEK or ERK, thereby inhibiting compensatory survival signaling and restoring the efficacy of BRAF-targeted therapies (Vella et al., 2017). The gene discussed is BRAF; the disease is melanoma.